Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + spironolactone
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metformin combined with spironolactone is a therapeutic combination used primarily for polycystic ovary syndrome (PCOS). This combination leverages complementary mechanisms of action: metformin acts as an insulin sensitizer to improve glucose metabolism and reduce insulin resistance, while spironolactone functions as an antiandrogen medication to reduce elevated androgen levels. Clinical studies have shown that this combination may be more effective than either drug alone in reducing BMI, serum androgen levels, improving menstrual cycle frequency, and enhancing insulin sensitivity in PCOS patients.
- Other names
- Metformin and SpironolactoneMetformin/Spironolactone combination
02
Targets
AR (Adrenergic receptors)INSR (Insulin receptor)
Beyond the preview
Go deeper on metformin + spironolactone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + spironolactone.